• Go to navigation
  • Go to content
AstraZeneca Clinical Trials

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca US

Main navigation

  • Home
  • Therapy Areas
    • Oncology/Infection
    • Cardiovascular
    • Gastrointestinal
    • Neuroscience
    • Respiratory/Inflammation
  • Drug Products
    • All Drug Products
  • Diseases & Conditions
    • All Diseases and Conditions
  • Glossary
  • Contact Us
  • Disclosure Commitment

You are here

  • Home
  • Total number of clinical trials

  • Expand All
  • Collapse All
  • Pages
  • Previous
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • Next
  • collapse A Phase 3, randomised, open-label, crossover study to compare HFA vs CFC pMDI formulations of budesonide on methacholine hyper-reactivity in patients with stable, persistent, mild to moderate asthma
  • collapse Phase II, Open Label, Non-Randomized Study of AZD2281 in the Treatment of Patients with Known BRCA or Recurrent High Grade Serous/ Undifferentiated Tubo-Ovarian Carcinoma and in Known BRCA or Triple Negative Breast Cancer to Determine Response Rate and Correlative Markers of Response
  • collapse The use of a forecasting system for predicting exacerbations of COPD: effect on symptoms and hospitalisation and relevance of viral infections
  • collapse Faslodex Post Marketing Surveillance
  • collapse A Single-centre, Double-blind, Double-dummy, Randomised, Placebo-controlled, Four-period Crossover Study to Assess the Effect of Single Oral Doses of AZD5672 (600 mg and 150 mg) on QT/QTc Interval, Compared to Placebo, using Moxifloxacin (Avelox) as a Positive Control, in Healthy Male Volunteers
  • collapse A single-centre, double-blind, randomised, parallel group study of repeated oral doses of AZD3480/placebo and a single dose of aripiprazole to evaluate the pharmacokinetic interaction between AZD3480 and aripiprazole in healthy subjects (phase I)
  • collapse A single-centre, double blind, randomised, two-way cross-over study of repeated doses of AZD3480 and single dose of warfarin to evaluate the pharmacokinetic interaction of AZD3480 and warfarin and the effect of AZD3480 pharmacodynamic in healthy male subjects (phase I)
  • collapse A double-blind, randomised, cross-over, placebo-controlled study of repeated oral doses of AZD3480 and a single dose of donepezil to evaluate the pharmacokinetic interaction between AZD3480 and donepezil in healthy extensive and poor metabolisers of CYP2D6
  • collapse A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD4547 in Patients with Advanced Solid Malignancies
  • collapse Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral AZD2423 After Single Ascending Doses in Healthy Japanese Male and Non-Fertile Female Volunteers
  • Pages
  • Previous
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • Next
  • Expand All
  • Collapse All

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2013